|
Adaptimmune Therapeutics Plc (NASDAQ: ADAP) |
|
Adaptimmune Therapeutics Plc
ADAP's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Adaptimmune Therapeutics Plc growth rates, revenue grew
by 354.13 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1674
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.29 %
Adaptimmune Therapeutics Plc net loss decreased from $-46 millions, to $-18 millions in III. Quarter 2024,
• More on ADAP's Growth
|
|
Adaptimmune Therapeutics Plc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 35 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 5.08.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.46.
• More on ADAP's Valuation
|
|
|
|
|
Adaptimmune Therapeutics Plc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 35 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 5.08.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.46.
Adaptimmune Therapeutics Plc Price to Book Ratio is at 11.53 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.02
• More on ADAP's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com